Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Fleeman N, Bagust A, Boland A et al. Fulvestrant for the treatment of locally advanced or metastatic breast cancer: a single technology appraisal (June 2011)

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • AstraZeneca

II Professional/specialist and patient/carer groups:

  • Breakthrough Breast Cancer

  • Breast Cancer Campaign

  • Breast Cancer Care

  • Macmillan Cancer Support

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

III Other consultees:

  • Department of Health

  • Welsh Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety, Northern Ireland

  • Healthcare Improvement Scotland

  • AstraZeneca

  • Pfizer

  • Liverpool Reviews and Implementation Group

  • National Institute for Health Research Technology Assessment Programme

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on fulvestrant by attending the initial Committee discussion and providing written evidence to the Committee. They are invited to comment on the ACD.

  • Dr Andreas Makris, Consultant Clinical Oncologist, nominated by Royal College of Physicians – clinical specialist

  • Tara Beaumont, Clinical Nurse Specialist, nominated by Breast Cancer Care – patient expert

  • Marie Hecht, nominated by Breast Cancer Care – patient expert

D Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • AstraZeneca

  • National Institute for Health and Care Excellence (NICE)